What We Have Done

What We Have Done 2017-10-13T09:40:33+00:00

OUR  EXPERIENCE

Cabernet Pharmaceuticals has assembled scientists and project managers with deep experience in applying pharmacogenetics (PGx) to all phases of drug development and to drug discovery as well. Previously, they conceived and executed PGx studies while holding direct or collaborative roles at large pharmaceutical corporations, biotechnology companies, and academic research institutions. Now they continue that pioneering work within the consultancy network of Cabernet and its sister company, Zinfandel Pharmaceuticals.

Our staff have consulted for or collaborated with partners in pharma (Eli Lilly and Company; Merck; Takeda Pharmaceutical Company Limited; Astellas Pharma US, Inc.; Daiichi-Sankyo Company, Limited), biotechs (Cancer Guide Diagnostics, Nebbiolo Technologies), and academia (Duke University, Northwestern University, Rush University, University of Ottawa Heart Institute, Murdoch University, Perron Institute for Neurological and Translational Science).

Examples of their contributions appear below.

Late Development –
Marketed Products

Pioglitazone
Prasugrel
Abacavir

Early Development –
Proof of Concept

Opioid-receptor antagonist
Evacetrapib
CCK-A receptor agonist
Rosiglitazone

Discovery

Alzheimer’s Disease Risk Biomarker